

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Section 1: Identification

Product name : Ribavirin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification

GHS Classification

Germ cell mutagenicity : Category 2

Reproductive toxicity : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H341 Suspected of causing genetic defects.
H360Df May damage the unborn child. Suspected of damaging fertility.
H373 May cause damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

P201 Obtain special instructions before use.

P260 Do not breathe mist or vapours.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	>= 30 -< 50
Glycerine	56-81-5	>= 20 -< 30
Propylene glycol	57-55-6	>= 20 -< 30
Ribavirin	36791-04-5	>= 1 -< 10

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms : Suspected of causing genetic defects.

Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

and effects, both acute and delayed	May damage the unborn child. Suspected of damaging fertility. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Sucrose	57-50-1	WES-TWA	10 mg/m ³	NZ OEL
Propylene glycol	57-55-6	WES-TWA (particulate)	10 mg/m ³	NZ OEL

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023 Date of first issue: 10.12.2015

		WES-TWA (Vapour and particulates)	150 ppm 474 mg/m ³	NZ OEL
Glycerine	56-81-5	WES-TWA (Mist)	10 mg/m ³	NZ OEL
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m ³ (OEB 3)	Internal

Engineering measures

- Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection

- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type

Hand protection

- Combined particulates and organic vapour type

Material

- Chemical-resistant gloves

Remarks

Eye protection

- Consider double gloving.
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance

- liquid

Colour

- clear

Odour

- No data available

Odour Threshold

- No data available

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

pH	:	4.8 - 5.5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle size	:	Not applicable

Section 10: Stability and reactivity

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Glycerine:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

Propylene glycol:

Acute oral toxicity : LD50 (Rat): 22,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 44.9 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Ribavirin:

Acute oral toxicity : LD50 (Rat): 4,116 - 5,584 mg/kg
LD50 (Mouse): > 10,000 mg/kg
LD50 (Dog): >= 1,500 mg/kg

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 1,554 - 1,758 mg/kg
Application Route: Intraperitoneal

LD50 (Mouse): 1,268 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:

Glycerine:

Species : Rabbit
Result : No skin irritation

Propylene glycol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Ribavirin:

Remarks : No data available
May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Glycerine:

Species : Rabbit
Result : No eye irritation

Propylene glycol:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Ribavirin:

Remarks : No data available
May irritate eyes.

Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Propylene glycol:**

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

Ribavirin:

Remarks	:	No data available
---------	---	-------------------

Chronic toxicity**Germ cell mutagenicity**

Suspected of causing genetic defects.

Components:**Sucrose:**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
-----------------------	---	---

Glycerine:

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
-----------------------	---	---

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Propylene glycol:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Ribavirin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Rodent cell line
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test
Species: Rat
Result: negative

Test Type: Mouse Lymphoma
Species: Mouse
Result: positive

Test Type: Micronucleus test
Species: Mouse
Result: positive

Germ cell mutagenicity - Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Carcinogenicity

Not classified based on available information.

Components:

Glycerine:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Propylene glycol:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Ribavirin Liquid FormulationVersion
5.1Revision Date:
30.09.2023SDS Number:
402761-00019Date of last issue: 04.04.2023
Date of first issue: 10.12.2015**Ribavirin:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	6 Months
LOAEL	:	75 mg/kg body weight
Result	:	negative
Target Organs	:	Blood, Testes
Remarks	:	The mechanism or mode of action may not be relevant in humans.
Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	10 mg/kg body weight
Result	:	negative
Remarks	:	The mechanism or mode of action may not be relevant in humans.
Species	:	Mouse
Application Route	:	Oral
Exposure time	:	18 Months
Result	:	negative
Remarks	:	The mechanism or mode of action may not be relevant in humans.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**Glycerine:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

Propylene glycol:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Mouse Application Route: Ingestion Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Mouse Application Route: Ingestion Result: negative

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

Ribavirin:

Effects on fertility

: Test Type: Fertility
Species: Rat, male
Application Route: Intraperitoneal injection
Fertility: LOAEL: < 20 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Mouse, male
Application Route: Oral
Fertility: LOAEL: 35 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Rat, females
Application Route: Oral
Fertility: NOAEL: 10 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 160 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development

: Test Type: Development
Species: Rat, female
Application Route: Oral
Developmental Toxicity: LOAEL: <= 1 mg/kg body weight
Symptoms: Reduced body weight, Reduced number of viable fetuses, Skeletal malformations
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Rabbit, female
Application Route: Oral
General Toxicity Maternal: LOAEL: 1 mg/kg body weight
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Reduced body weight, Skeletal malformations
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Hamster
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Symptoms: Skeletal and visceral variations, Total Resorptions / resorption rate

Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.3 mg/kg body weight
Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Skeletal malformations
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Ribavirin:**

Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Components:**Ribavirin:**

Exposure routes : Ingestion
Target Organs : Blood
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Glycerine:**

Species : Rat
NOAEL : 0.167 mg/l
LOAEL : 0.622 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 13 Weeks

Species : Rat
NOAEL : 8,000 - 10,000 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Species : Rabbit

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023 Date of first issue: 10.12.2015

NOAEL : 5,040 mg/kg
Application Route : Skin contact
Exposure time : 45 Weeks

Propylene glycol:

Species : Rat, male
NOAEL : >= 1,700 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Ribavirin:

Species : Monkey
LOAEL : 30 mg/kg
Exposure time : 10 d
Target Organs : Blood, Gastrointestinal tract

Species : Rat
NOAEL : 7.6 mg/kg
Application Route : Inhalation
Exposure time : 90 d
Target Organs : Blood, Lungs

Species : Dog
NOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 1 yr
Target Organs : Blood, Gastrointestinal tract

Species : Mouse
NOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Blood, Cardio-vascular system

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ribavirin:

Inhalation : Symptoms: Headache, Dizziness
Remarks: Based on Human Evidence
Skin contact : Remarks: May cause eye irritation.
Based on Human Evidence
Eye contact : Remarks: May cause eye irritation.
Based on Human Evidence
Ingestion : Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver function change, Gastrointestinal disturbance

Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Section 12: Ecological information**Ecotoxicity****Components:****Glycerine:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Propylene glycol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l
Exposure time: 7 d

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 20,000 mg/l
Exposure time: 18 h

Ribavirin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 117 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 6.9 mg/l
Exposure time: 96 h

Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Glycerine:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 %
Exposure time: 30 d
Method: OECD Test Guideline 301D

Propylene glycol:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 98.3 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

Bioaccumulative potential**Components:****Sucrose:**

Partition coefficient: n-octanol/water : Pow: < 1

Glycerine:

Partition coefficient: n-octanol/water : log Pow: -1.75

Propylene glycol:

Partition coefficient: n-octanol/water : log Pow: -1.07
Method: Regulation (EC) No. 440/2008, Annex, A.8

Ribavirin:

Partition coefficient: n-octanol/water : log Pow: 0.971

Mobility in soil

No data available

Other adverse effects

No data available

Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1 Revision Date: 30.09.2023 SDS Number: 402761-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

not allocated

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

SAFETY DATA SHEET



Ribavirin Liquid Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 402761-00019	Date of last issue: 04.04.2023 Date of first issue: 10.12.2015
----------------	------------------------------	-----------------------------	---

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN